- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
"Not So Different" Episode 5: Policy and Biosimilars
“If legislators want to be able to tell their constituents that they acted on drug prices this year, this is the vehicle to do it. There is nothing else with this kind of support and with this kind of impact sitting before legislators right now,” said Christine Simmon, JD, executive director of the Biosimilars Council, about the bipartisan CREATES Act.
Our guest on this episode of “Not So Different” is Christine Simmon, JD, the executive director of the Association for Accessible Medicines’ (AAM) Biosimilars Council.
Simmon joined The Center for Biosimilars® via phone to discuss recent comments from FDA Commissioner, Scott Gottlieb, MD, on challenges in the US biosimilars market, and a potential legislative solution—the bipartisan CREATES Act—that could help to address some of those challenges.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
